Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Philadelphia chromosome Stories

2012-10-29 11:49:48

Researchers locate molecules that drive the development of 3 forms of deadly white blood cell cancers, pointing researchers to new potential therapeutic targets A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and...

2012-08-13 22:03:30

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. The study focused on a subtype of acute lymphoblastic leukemia (ALL) known as Philadelphia...

2012-08-13 06:25:12

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer MEMPHIS, Tenn., Aug. 13, 2012 /PRNewswire-USNewswire/ -- Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. The study focused on a subtype of...

2012-08-05 18:21:55

Industry-Academic Partnership Will Establish New Research Center to Expedite Study and Development of Gene Transfer Approach PHILADELPHIA, Aug. 6, 2012 /PRNewswire-USNewswire/ -- In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric...

2012-07-25 02:29:04

SUNNYVALE, Calif., July 25, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert(®) BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert(®) System, detects the BCR-ABL mRNA transcript in the...

2012-06-18 23:16:24

Leukemia patients 16 to 39 have higher long-term survival rates, finds TAU researcher Acute lymphoblastic leukemia (ALL), usually found in pediatric patients, is far more rare and deadly in adolescent and adult patients. According to the National Marrow Donor Program, child ALL patients have a higher than 80 percent remission rate, while the recovery rate for adults stands at only 40 percent. In current practice, pediatric and young adult ALL patients undergo different treatment...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-15 10:23:01

PARIS, June 15, 2012 /PRNewswire/ -- Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R)...

2012-06-01 10:22:07

NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.(4)...

2012-04-12 09:20:25

International study that included St. Jude Children's Research Hospital reports some young acute lymphoblastic leukemia patients who fail induction therapy can achieve high cure rates without bone marrow transplantation An international study found that bone marrow transplants are not the best option for some young patients with acute lymphoblastic leukemia (ALL) who fail to attain clinical remission after the initial weeks of intense chemotherapy known as induction therapy. The largest...